title: Allergic reaction to abciximab with atypical manifestations.
abstract: Abciximab (ReoPro, Eli Lilly and Company, Indianapolis, Indiana) is an intravenous agent that had been approved for treatment of acute coronary syndrome undergoing coronary interventions. It is a chimeric monoclonal antibody fragment that binds to the glycoprotein IIb/IIIa receptor with a potential for the development of an immune response to variable portions within the antigen binding site following its administration. We describe a 58-year-old man who developed sudden headache, short of breath, choking and restlessness after receiving Abciximab for coronary intervention. Discontinuation of abciximab and administration of intravenous fluids, steroid and antihistamines led to improvement of his symptoms gradually.
authors: Riyadh Military Hospital, Prince Sultan Cardiac Centre (PSCC), Adult Cardiology Department, Riyadh 11427, Saudi Arabia.
authors: Abdulrahman M
authors: AM
authors: Al-Moghairi
authors: Moheeb A
authors: MA
authors: Abdullah
keywords: Abciximab; Allergic reaction; Coronary intervention; Glycoprotein IIb/IIIa inhibitor
references: Allergy. 2002 Mar;57(3):269-70
references: 11906353
references: Circulation. 2001 Aug 21;104(8):870-5
references: 11514371
references: Am J Cardiol. 2004 Apr 15;93(8):979-84
references: 15081439
references: Pharmacotherapy. 2002 Mar;22(3):380-3
references: 11898893
references: J Thromb Haemost. 2004 Jun;2(6):985-92
references: 15140135
references: N Engl J Med. 1994 Apr 7;330(14):956-61
references: 8121459
references: Clin Pharmacol Ther. 1981 Aug;30(2):239-45
references: 7249508
references: Cardiology. 2001;95(4):215-6
references: 11585998
references: Catheter Cardiovasc Interv. 1999 Sep;48(1):71-3
references: 10467075
references: Allergy. 2003 Jul;58(7):688-9
references: 12823141